modelM02AA21
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Tolmetin | |
| ATC code: | M02AA21 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 10 | L |
| clearance: | 1.0 | L/h |
| other parameters in model implementation | ||
Tolmetin is a non-steroidal anti-inflammatory drug (NSAID) previously used for the treatment of pain and inflammation associated with conditions like rheumatoid arthritis and osteoarthritis. Its use has declined and is currently discontinued or unavailable in many markets due to safety concerns and availability of alternative NSAIDs.
Pharmacokinetics
Pharmacokinetic parameters estimated for healthy adult subjects after oral administration, as no direct publications for tolmetin with ATC code M02AA21 (topical) were identified. Values are extrapolated from available data on oral tolmetin, as topical/systemic PK data for M02AA21 are absent in the literature.
References
Flores-Murrieta, FJ, et al., & Castañeda-Hernández, G (1998). Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach. Journal of pharmacokinetics and biopharmaceutics 26(5) 547–557. DOI:10.1023/a:1023273100270 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10205770
Mandema, JW, & Stanski, DR (1996). Population pharmacodynamic model for ketorolac analgesia. Clinical pharmacology and therapeutics 60(6) 619–635. DOI:10.1016/S0009-9236(96)90210-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8988064
Dupuis, LL, et al., & Laxer, RM (1990). Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. The Journal of rheumatology 17(11) 1469–1473. PUBMED:https://pubmed.ncbi.nlm.nih.gov/2273487
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)